

Register of AI Data Exclusivity Granted in Malaysia

For a Second indication of a registered drug product

As described and stipulated in "Direktif Penguatkuasaan Keperluan Melaksanakan Data Eksklusiviti di Malaysia" Bil. (11) BPFK/PPP/01/03 Jilid 1, dated 28 February 2011 and effective from 01 March 2011, Data Exclusivity has been granted by the Drug Control Authority, Ministry of Health Malaysia, for the Second indication of a registered product as listed below.

The period of Data Exclusivity is calculated from the date the Second indication is first approved AND granted Data Exclusivity in the country of origin or in any country recognised and deemed appropriate by the Director of Pharmaceutical Services.

No.	Registration (MAL) No.	Product Name	Active Ingredient	Manufacturer	DCA Reference Country for DE			DE Granted by DCA		
					Country	Registration Date	Exclusivity Expiration	Registration Date	Protection Period	Exclusivity Expiration
1	MAL20102019AR	Onglyza Tablet 2.5mg	Saxagliptin hydrochloride	Bristol-Myers Squibb Company, USA	USA	16-Dec-11	16-Dec-14	28-Jun-12	3 years	16-Dec-14
2	MAL20102020AR	Onglyza Tablet 5mg	Saxagliptin hydrochloride	Bristol-Myers Squibb Company, USA	USA	16-Dec-11	16-Dec-14	28-Jun-12	3 years	16-Dec-14
3	MAL11115002A	Xarelto 15mg film-coated tablet	Rivaroxaban 15mg	Bayer Pharma AG, Germany	USA	2-Nov-12	2-Nov-15	28-Mar-13	3 years	2-Nov-15
4	MAL11115001A	Xarelto 20mg film-coated tablet	Rivaroxaban 20mg	Bayer Pharma AG, Germany	USA	2-Nov-12	2-Nov-15	28-Mar-13	3 years	2-Nov-15
5	MAL13065048A	Stivarga 40mg Film-coated Tablets	Regorafenib monohydrate 41.49mg (equivalent to 40mg regorafenib)	Bayer Pharma AG, Germany	USA	25-Feb-13	25-Feb-16	23-Jan-14	3 years	25-Feb-16

DCA: Drug Control Authority; DE: Data Exclusivity